Ensysce Biosciences
Dr. Kirkpatrick has focused her entire career on drug discovery and development. Former Professor of Chemistry and Biochemistry in Canada, she has co-founded two start up companies and successfully brought three novel cancer drug candidates into human clinical trails.
Following the acquisition of her first company, by Biomira Inc., (Oncothyreon) in 2006, Dr. Kirkpatrick took the role as the Chief Scientific Officer of the merged company. She became President and CEO of Ensysce Biosciences Inc. in January 2009.
Dr. Kirkpatrick received her PhD from the University of Saskatchewan and completed a post-doctoral fellowship at Yale University School of Medicine. She has published extensively in the area of targeted drug discovery and development and holds numerous patents for novel targeted drugs and delivery technology.
This person is not in any offices
Ensysce Biosciences
1 followers
Ensysce Biosciences, Inc. (Ensysce) is a clinical-stage biotech company developing a new class of prescription drugs that will provide patients and prescribers safer options for the use of potent prescription drugs, reducing abuse and preventing overdoses.